With much of the healthcare investment world in San Francisco for the annual J.P. Morgan Healthcare Conference, the deals will be coming fast and furious this week. Here is a roundup of the activity at and away from JPM in the last 24 hours.
UnitedHealthGroup’s OptumCare subsidiary is making a big move into the provision of surgery by acquiring Surgical Care Affiliates for $2.3 billion, or $57 per share. Deerfield, Illinois-based SCA operates 205 ambulatory surgical centers and surgical hospitals in 30 states.
At ViVE 2024, Panelists Share Prior Authorization Progress and Frustration in Payer Insights Program
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
Takeda Pharmaceutical Co. is ponying up $5.2 billion to acquire Ariad Pharmaceuticals of Cambridge, Massachusetts. The price of $24 per share represents a whopping premium of 75 percent over the Friday closing.
Aledade, which offers analytics and other IT to support accountable care, has closed on a $20 million funding round, led by Biomatics Capital. Aledade’s CEO is former national health IT coordinator Dr. Farzad Mostashari, who said the company will expand into the Medicare Advantage market.
Predictive analytics company PeraHealth locked up $14 million in growth capital from Mainsail Partners.
SnapMD, which provides telemedicine technology for “virtual care management,” brought in a $3.25 million extension to its Series A round. The round is now worth a total of $9.15 million.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Ivantis, an Irvine, California-based device company focused on eye health, closed a $25 million Series C round. The company will use the money to commercialize its Hydrus microstent for lowering eye pressure in people with glaucoma.
Photo: Flickr user s_falkow
